Kiniksa Pharmaceuticals slides after quarterly update

Kiniksa Pharmaceuticals International

03/08/2021 20:52

** Shares in clinical stage biopharmaceutical co Kiniksa
Pharmaceuticals  KNSA.O  down 17.9% at $13.33 after Q2 financial
results, update of drug development
    ** KNSA reported net loss of $0.61/shr vs Wall Street
expectations for a loss of $0.79/shr on rev of $7.7 mln vs
consensus expectation for $3.97 mln  urn:newsml:reuters.com:*:nGNX5Qzcqh
    ** KNSA, which started generating revenue from its ARCALYST
treatment for recurrent pericarditis during the quarter, said
enrolling non-mechanically ventilated patients for a phase 3
trial of mavrilimumab for COVID-19 related ARDS
    ** Trading volume 4 times 10-DMA, on track for biggest
one-day pct decline since mid March
    ** Median PT is $33 with 2 analyst rating KNSA 'strong buy'
and 3 rating it 'buy'

 (Reporting By Sinéad Carew)
 ((sinead.carew@thomsonreuters.com; +1 (646) 223 6186; Reuters
Messaging: sinead.carew.thomsonreuters.com@reuters.net))